1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
GL Pharm Tech Corp.

GL Pharm Tech Corp.

KKRX:204840
3,595.00
KRW
-110.00
(-2.97%)
-6.79EPS
64.44BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
1,404.92
765.95
369.84
1,139.33
1,461.75
1,339.38
1,216.78
1,376.1
2,083.47
1,727.27
2,286.39
2,421.93
Basic EPS, GAAP
-21.02
235.2
-907.86
-649.14
-762.04
-760
-375
-365
-65
-300
-155
0.81
-6.79
Free Cash Flow per Basic Share
-42.96
424.73
-739.56
-703.58
-1,026.23
-286.51
-420.6
-353.28
-634.55
-347.25
-424.04
-359.57
-212.22
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
8,820.21
2,818.18
1,333.76
880.23
1,027.53
329.99
1,462.92
1,362.02
1,295.45
984.88
1,277.72
1,284.28
1,282.39
Tangible Book Value per Share
8,820.21
2,702.25
1,315.16
859.64
335.53
-107.01
1,184.8
1,207.12
1,176.37
902.48
1,168.58
1,199.55
1,195.02
Basic Weighted Avg Shares
- -
5
6
7
7
7
9
10
12
12
15
15
16
Sales/Revenue/Turnover
- -
6,475
4,636
2,414
7,998
10,608
11,988
12,426
16,729
26,033
26,048
35,268
38,205
Operating Margin (%)
- -
14.5
-59.64
-175.98
-57.25
-29.48
-22.06
-21.68
-19.46
-12.4
-6.79
0.76
0.59
Depreciation Expense
- -
195
275
401
1,145
1,848
1,949
2,040
2,145
2,138
1,710
1,002
1,135
Net Income, GAAP
-7
1,084
-5,494
-4,237
-5,350
-5,515
-3,356
-3,727
-790
-3,749
-2,337
12
-107
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
83.57
- -
Profit Margin (%)
- -
16.74
-118.53
-175.52
-66.88
-51.99
-28
-30
-4.72
-14.4
-8.97
0.04
-0.28
Working Capital
9,834
2,150
6,191
5,246
3,376
-9,812
8,308
8,404
3,086
4,301
5,100
222
-442
LT Debt
1,364
420
132
3,501
12,372
3,735
8,767
5,560
7,458
11,327
5,877
4,405
4,648
Total Equity
8,438
2,696
8,568
5,935
7,817
2,362
14,315
17,480
16,090
12,282
19,668
19,919
19,890
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.12
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.3
- -
Return on Common Equity (%)
- -
19.47
-97.55
-58.42
-77.8
-108.38
-41.5
-24.31
-4.8
-26.42
-14.63
0.06
-0.54

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14,328
17,279
16,231
LT Borrowings
4,180
3,118
4,420
LT Finance Leases
224
227
228
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
84,606
80,651
64,443

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
21,666
21,574
21,212
Cash, Cash Equivalents & STI
3,036
3,146
3,459
Accounts Receivable, Net
7,108
7,399
6,495
Inventories
10,956
10,638
10,987
Total Current Liabilities
21,444
22,640
21,654
Payables & Accruals
- -
- -
- -
ST Debt
14,328
17,279
16,231
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.7%
10.38%
1.28%
Free Cash Flow
-15.93%
20%
-13.27%
Net Income, GAAP
-47.11%
33.7%
-100.53%
Sales/Revenue/Turnover
33%
25.87%
35.4%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,834
6,967
4,681
8,566
26,048
2025
7,839
8,359
9,535
9,535
35,268
2026
9,434
9,702
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-120
-45
-10
6.07
-155
2025
0.31
5
8.42
-12.99
0.81
2026
-7.74
5
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
32
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Seongnam-si South Korea
IPO Date
Nov 20, 2014
Website
glpt.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
GL Pharm Tech Corp. is a South Korea-based specialty pharmaceutical company primarily engaged in the research, development, formulation, and commercialization of incrementally modified drugs, novel drug delivery system technologies, and finished pharmaceutical products. The company provides a broad range of therapeutic formulations and pharmaceutical services, including sustained-release central nervous system and neuropathic pain medications; gastrointestinal therapies for gastritis and gastroesophageal reflux disease; cardiovascular and metabolic disease agents; ophthalmic solutions and suspension therapies for dry eye syndrome; urological formulations; contract development and manufacturing organization services; formulation development and bioequivalence testing; and domestic and international technology licensing and transfer solutions. The company conducts commercial-scale manufacturing and distribution through its subsidiary, GL HanPook Pharm Co., Ltd., operating certified Good Manufacturing Practice production facilities. In recent developments, GL Pharm Tech Corp. has advanced the clinical development and domestic commercialization of its proprietary modified-release drug candidates and ophthalmic pipeline, expanded strategic co-development and supply agreements with domestic pharmaceutical partners, upgraded its finished dosage manufacturing infrastructure to scale production capacity, and executed capital financing initiatives to support late-stage clinical trials and formulation pipeline expansion. Founded in 2002, GL Pharm Tech Corp. is headquartered in Seongnam-si, Gyeonggi-do, South Korea, and operates primarily in South Korea with growing business and licensing partnerships across international markets.